EC Healthcare (HK:2138)
:2138
Want to see HK:2138 full AI Analyst Report?
2138 Stock Chart & Stats
HK$0.57
-HK$0.01(-1.61%)
At close: 4:00 PM EST
HK$0.57
-HK$0.01(-1.61%)
Day’s Range― - ―
52-Week RangeHK$0.44 - HK$1.20
Previous CloseN/A
Volume263.00K
Average Volume (3M)629.78K
Market Cap
HK$551.12M
Enterprise ValueHK$1.30B
Total Cash (Recent Filing)HK$1.07B
Total Debt (Recent Filing)HK$1.34B
Price to Earnings (P/E)―
Beta1.46
Next Earnings
Jun 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.72%
Share Statistics
EPS (TTM)-0.14
Shares Outstanding1,185,211,300
10 Day Avg. Volume673,306
30 Day Avg. Volume629,783
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.46
Price to Sales (P/S)0.20
P/FCF Ratio1.19
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.02
Revenue Forecast (FY)HK$5.02B
Bulls Say, Bears Say
Bulls Say
High Gross MarginAn 80.7% gross margin indicates the services business has strong pricing power and low direct costs, supporting core profitability. This structural margin provides a durable buffer while management works to restore volumes, enabling reinvestment or margin recovery when demand improves.
Free Cash Flow StrengthPositive FCF growth and a FCF-to-net-income ratio near parity show the company generates cash even amid accounting losses. Durable cash generation supports working capital, debt service and selective investment without immediate capital raises, improving resilience over coming quarters.
Moderate LeverageA debt-to-equity around 0.75 suggests leverage is manageable, giving financial flexibility to absorb revenue volatility. Stable equity financing proportions reduce refinancing risk and allow time for operational fixes or strategic initiatives without forcing distressed capital actions.
Bears Say
Steep Revenue DeclineA near 30% revenue drop signals material demand erosion or lost market share. Reduced scale undermines fixed-cost absorption, compresses operating leverage, and limits the company’s ability to invest in growth or marketing. This structural revenue weakness risks prolonged margin pressure.
Negative Profitability / ROESustained negative net margin and ROE indicate the business is not generating returns above its capital cost, eroding shareholder value. Persistent losses constrain retained earnings, limit dividend prospects, and make external capital more costly, restricting strategic options long-term.
Declining Operating MarginsFalling EBIT/EBITDA margins point to operational inefficiencies or fixed-cost pressure as volumes drop. Unless addressed by cost restructuring or revenue recovery, lower operating margins will reduce cash flows and hamper reinvestment, prolonging recovery even if top-line stabilizes.
EC Healthcare News
2138 FAQ
What was EC Healthcare’s price range in the past 12 months?
EC Healthcare lowest stock price was HK$0.43 and its highest was HK$1.20 in the past 12 months.
What is EC Healthcare’s market cap?
EC Healthcare’s market cap is HK$551.12M.
When is EC Healthcare’s upcoming earnings report date?
EC Healthcare’s upcoming earnings report date is Jun 18, 2026 which is in 43 days.
How were EC Healthcare’s earnings last quarter?
EC Healthcare released its earnings results on Nov 28, 2025. The company reported -HK$0.009 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.009.
Is EC Healthcare overvalued?
According to Wall Street analysts EC Healthcare’s price is currently Overvalued.
Does EC Healthcare pay dividends?
EC Healthcare pays a Annually dividend of HK$0.01 which represents an annual dividend yield of 1.72%. See more information on EC Healthcare dividends here
What is EC Healthcare’s EPS estimate?
EC Healthcare’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does EC Healthcare have?
EC Healthcare has 1,185,211,300 shares outstanding.
What happened to EC Healthcare’s price movement after its last earnings report?
EC Healthcare reported an EPS of -HK$0.009 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.667%.
Which hedge fund is a major shareholder of EC Healthcare?
Currently, no hedge funds are holding shares in HK:2138
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
EC Healthcare Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-19.02%
12-Months-Change
Fundamentals
Return on Equity
-10.69%
Trailing 12-Months
Asset Growth
-3.74%
Trailing 12-Months
Company Description
EC Healthcare
EC Healthcare, an investment holding company, engages in the provision of medical and healthcare services in Hong Kong, Macau, and the People's Republic of China. The company operates through three segments: Medical, Aesthetic Medical and Beauty and Wellness, and Others. It provides quasi-medical, beauty and wellness, medical imaging, medical surgery, aesthetic medical beauty, aesthetic medical, dental, hair treatment, vaccine, chiropractic, psychological, and orthopedics services. It also offers administrative, management, laboratory testing, performance marketing, marketing, and travel agency services; sells beauty and skincare products; operates in healthcare machines and property investment holding businesses; and provides multi-channel networking and related services, and veterinary services. The company offers products and services primarily under private-label brands, such as PRODERMA LAB, Swissline, Suissebeaute, and re:HEALTH. The company was formerly known as Union Medical Healthcare Limited and changed its name to EC Healthcare in April 2021. EC Healthcare was founded in 2005 and is headquartered in Mong Kok, Hong Kong.
Technical Analysis
Natural Beauty Bio-Technology
―
China Ludao Technology Co. Ltd.
―
Shanghai Chicmax Cosmetics Co., Ltd. Class H
―
Giant Biogene Holding Co. Ltd.
―
Nanjing Sinolife United Co., Ltd. Class H
―
Options Prices
Currently, No data available
---